Theilig D, Elkilany A, Jann H, et al. - A total of 129 individuals with neuroendocrine tumors (NETs) who underwent two or more serial gadoxetic-acid-enhanced MRI examinations among 2014 and 2018 and began chemotherapy at the commencement of that time period were retrospectively reviewed, in order to estimate the hepatotoxicity of various chemotherapeutic agents utilized to treat NETs with gadoxetic acid-enhanced MRI. Linear mixed model analysis of a total of 539 MRI examinations recognized all chemotherapeutic agents with known hepatoxicity as a factor with a statistically important negative influence on relative enhancement of the liver in gadoxetic-acid-enhanced MRI in addition to age. This result was validated by binary logistic regression analysis. In summary, gadoxetic acid-enhanced MRI could be utilized as an imaging-based liver function test for evaluating the hepatotoxicity of chemotherapeutic agents used for NETs. Moreover, the outcomes underscore the familiar degrees of hepatotoxicity of the chemotherapeutic agents up to date utilized in the treatment of NETs.